Key result
Multimodality cardiac imaging guides the diagnosis, classification, and management of cardiomyopathies.
Multimodality imaging plays a central role in the diagnosis and management of cardiomyopathies, and should be integrated with clinical and genetic data.
Supports integrated multimodality imaging with clinical-genetic data in cardiomyopathies; leaves open protocol standardization and outcome trials.
Imaging has a central role in the diagnosis, classification, and clinical management of cardiomyopathies. While echocardiography is the first-line technique, given its wide availability and safety, advanced imaging, including cardiovascular magnetic resonance (CMR), nuclear medicine and CT, is increasingly needed to refine the diagnosis or guide therapeutic decision-making. In selected cases, such as in transthyretin-related cardiac amyloidosis or in arrhythmogenic cardiomyopathy, the demonstration of histological features of the disease can be avoided when typical findings are observed at bone-tracer scintigraphy or CMR, respectively. Findings from imaging techniques should always be integrated with data from the clinical, electrocardiographic, biomarker, genetic and functional evaluation to pursue an individualised approach to patients with cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Castiglione et al. (2023) conducted a review in Cardiomyopathies. Multimodality cardiac imaging was evaluated. Multimodality cardiac imaging, including echocardiography, CMR, nuclear medicine, and CT, plays a central role in the diagnosis, classification, and clinical management of cardiomyopathies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: